NCT01647308

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Ionis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	ISIS-APOCIIIRX	3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
DRUG	Placebo	3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.

Timeline

• Start date: 2012-07-01
• Primary completion: 2014-01-01
• Completion: 2014-03-01
• First posted: 2012-07-23
• Last updated: 2022-01-18

Locations

1 site across 1 country: United States